<DOC>
	<DOCNO>NCT01280656</DOCNO>
	<brief_summary>This retrospective study ass sustain virologic response safety two different interferon ( pegylated conventional ) patient chronic hepatitis C. Data collect 24 week .</brief_summary>
	<brief_title>A Retrospective Study Assess Impact Use Interferon Patients With Chronic Hepatitis C ( DECISION )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , &gt; /=18 year &lt; 70 year age Diagnosis hepatitis C Assessment viral load prior treatment ( mandatory genotype 1 ) Liver biopsy Comorbidities data Use interferon ( pegylated conventional ) ribavirin treat hepatitis C infection genotype 2 3 pegylated interferon plus ribavirin treat hepatitis C infection genotype 1 Above mention treatment start 01Sep2007 31Aug2008 Coinfection human immunodeficiency virus Coinfection hepatitis B virus Presence hepatocarcinoma Patients submit hemodialysis Organ transplant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>